Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Adjuvant interferon-alpha in malignant melanoma: current status.

B W Hancock¹, S Harris, K Wheatley

¹Weston Park Hospital, Sheffield.

Cancer Treatment Reviews

|April 22, 2000

Summary

Adjuvant therapy with recombinant interferon may offer a clinical benefit for high-risk melanoma patients, improving relapse-free survival. However, its use is not yet standard due to the need for further evaluation of benefits, doses, and cost-effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity-Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024

Same author

FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis.

Systematic reviews·2020

Same author

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.

European journal of cancer (Oxford, England : 1990)·2019

Same author

Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?

European journal of obstetrics, gynecology, and reproductive biology·2019

Area of Science:

Oncology
Immunology
Dermatology

Background:

High-risk cutaneous malignant melanoma has a poor prognosis, with less than 50% 5-year survival after surgical resection.
Adjuvant therapy is indicated for such cases, with a focus on biological agents due to the role of immunological control in melanoma.
Recombinant interferon has been extensively studied as an adjuvant therapy.

Purpose of the Study:

To evaluate the efficacy of adjuvant recombinant interferon in patients with high-risk surgically resected primary or loco-regional cutaneous malignant melanoma.

Main Methods:

Analysis of data from over 4000 patients entered into randomized adjuvant studies of recombinant interferon.
Assessment of clinical benefits, including relapse-free and overall survival.

Related Experiment Videos

Main Results:

Results suggest a potential clinical benefit from recombinant interferon, particularly in improving relapse-free survival.
A possible benefit in overall survival was also observed, though less pronounced.

Conclusions:

Recombinant interferon shows promise as an adjuvant therapy for high-risk melanoma, but further research is needed.
Precise estimates of benefit magnitude, optimal doses, schedules, and cost-benefit analyses are required.
Interferon is not currently recommended as standard adjuvant therapy for high-risk malignant melanoma.